Enliven Therapeutics, Inc. (ELVN)
| Market Cap | 1.24B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -85.21M |
| Shares Out | 48.86M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 149,651 |
| Open | 26.25 |
| Previous Close | 26.18 |
| Day's Range | 24.98 - 26.48 |
| 52-Week Range | 9.80 - 30.03 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 36.75 (+44.51%) |
| Earnings Date | Nov 13, 2024 |
About ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ELVN stock is "Strong Buy." The 12-month stock price forecast is $36.75, which is an increase of 44.51% from the latest price.
News
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose redu...
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
BOULDER, Colo. , Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of...
Why Enliven is this analyst's top biotech stock pick
Salim Syed, Mizuho Americas managing director and senior analyst, joins the latest edition of Good Buy or Goodbye to discuss his top and bottom picks in the pharmaceutical industry. Syed points to Enl...
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Updated Phase 1 data presented at ESH-iCMLf 26 th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, whi...
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and developm...
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-gener...
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and developm...
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and developm...
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 a...
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024
Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation s...
Enliven Therapeutics: Preclinical Company With Interesting Value Proposition
Enliven Therapeutics, Inc. is a recently merged biopharma company focused on developing oncology candidates for leukemia and lymphoma. The company has raised $165 million in a private placement to fun...
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024
Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
Combined company will be focused on advancing Enliven's clinical-stage pipeline of precision oncology programs
Imara Announces Stockholder Approval of Merger With Enliven
-- Combined Company to Trade on Nasdaq Under Ticker “ELVN” -- -- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: ...
IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Imara Inc. (...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FCRD, KNBE, IMRA
NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...
Enliven Therapeutics and Imara Announce Merger Agreement
Boulder, CO and Boston, MA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generat...
Imara: Potential Liquidation
Imara has announced strategic alternatives and has announced the sale its key asset. It now trades 37% below its Pro Forma net cash levels and a liquidation would be ideal.
Read Why Imara Shares Are Falling Today
Imara Inc (NASDAQ: IMRA) shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia. Da...
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat popu...
Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript
Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript
Imara Reports Full Year 2021 Financial Results and Business Highlights
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022